Back to Blog

Peptides for PTSD: Selank, Semax, BPC-157, and Neuroplasticity Research

March 25, 2026·7 min read

Post-traumatic stress disorder (PTSD) is a debilitating condition affecting an estimated 20 million adults in the United States alone. Current pharmacological treatments — primarily SSRIs and SNRIs — provide incomplete relief for many patients. The search for novel approaches has led researchers toward peptides that target fear memory consolidation, neuroinflammation, and the neuroplasticity deficits that underlie PTSD's core symptoms.

This review examines the evidence for several peptides with potential relevance to PTSD: Selank, Semax, BPC-157, and cerebrolysin.

Understanding PTSD Biology

PTSD is fundamentally a disorder of fear memory — specifically, the failure to extinguish conditioned fear responses following trauma. The amygdala, hippocampus, and prefrontal cortex are the key brain regions involved. Neurobiologically, PTSD is characterized by:

  • Hyperactivation of the amygdala (threat response)
  • Reduced hippocampal volume (associated with impaired contextual memory)
  • Reduced prefrontal inhibitory control over the amygdala
  • Elevated cortisol and CRH (corticotropin-releasing hormone) signaling
  • Neuroinflammation
  • Impaired BDNF signaling and neurogenesis

Effective treatments for PTSD tend to work through one or more of these pathways. Peptides are of interest precisely because several act on multiple pathways simultaneously.

Selank: Fear Extinction and Anxiolytic Effects

Selank is a synthetic analog of the immunomodulatory peptide tuftsin. It has been studied in Russia for generalized anxiety disorder and related conditions with strong overlap with PTSD symptomatology.

Mechanisms relevant to PTSD: Selank enhances serotonin metabolism and increases BDNF expression in the hippocampus. Both effects are mechanistically relevant: BDNF supports fear extinction learning, which is the neurobiological basis of prolonged exposure therapy — the gold-standard psychotherapy for PTSD. Selank also reduces corticotropin levels and blunts stress-axis hyperreactivity without causing sedation.

Animal research: Rodent studies using fear conditioning paradigms show that Selank facilitates extinction of conditioned fear responses and reduces avoidance behavior. These behavioral correlates map directly onto PTSD's avoidance and re-experiencing symptoms.

Clinical relevance: While no clinical trials have specifically targeted PTSD diagnosis, Selank's Phase II/III trial data for anxiety disorders — which share substantial neurobiology with PTSD — suggests anxiolytic efficacy without dependence risk, an important advantage over benzodiazepines which are generally contraindicated in PTSD.

For administration details, see our intranasal peptides guide. Selank's full profile is covered in our Selank peptide guide.

Semax: BDNF Upregulation and Stress Response

Semax is a synthetic heptapeptide derived from ACTH (adrenocorticotropic hormone). Its primary research interest lies in its potent upregulation of neurotrophins — BDNF and NGF in particular.

BDNF and trauma recovery: BDNF is critical for hippocampal neurogenesis and synaptic plasticity. PTSD patients consistently show reduced hippocampal volume and BDNF levels compared to trauma-exposed individuals without PTSD. By robustly increasing BDNF, Semax addresses a core biological vulnerability in PTSD.

HPA axis normalization: Semax has been shown to reduce stress-induced elevations in ACTH and corticosterone in animal models. Since PTSD is characterized by dysregulated HPA axis activity — often manifesting as elevated CRH with variable cortisol patterns — this effect is directly relevant.

Neuroinflammation: Semax reduces expression of inflammatory genes in the brain, including IL-6 and TNF-α. Emerging evidence implicates neuroinflammation in PTSD maintenance, particularly in treatment-resistant presentations.

Dosing in research contexts: Intranasal doses of 200–600 mcg once or twice daily are most commonly reported. See our Semax peptide guide for a full review.

BPC-157: Systemic Stress Protection and Neuromodulation

BPC-157 (Body Protection Compound-157) is a pentadecapeptide with wide-ranging cytoprotective and neuromodulatory effects. Its relevance to PTSD spans several mechanisms.

Dopaminergic protection: PTSD involves significant dopaminergic dysregulation — reduced reward signaling contributes to anhedonia, while amygdala dopamine excess may amplify threat responses. BPC-157 modulates dopamine synthesis and release and has been shown in rodent models to normalize dopaminergic tone after stress-induced disruption.

Gut-brain axis in PTSD: There is growing evidence that gut microbiome dysbiosis contributes to PTSD vulnerability and maintenance. BPC-157's well-documented effects on gut mucosal integrity, motility, and the enteric nervous system may have upstream effects on central neurotransmitter availability — particularly serotonin, given that the vast majority is produced in the gut.

Physical comorbidities: PTSD patients have elevated rates of pain conditions, IBS, and inflammatory disorders. BPC-157's systemic anti-inflammatory and tissue-healing effects may address these comorbidities, improving overall quality of life even if direct PTSD symptom reduction is less certain. For gut-specific BPC-157 applications, see our peptides for gut healing guide.

Our complete BPC-157 guide covers the full mechanism and protocol details.

Cerebrolysin: Neuroprotection and Neuroregeneration

Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pig brain tissue. It has a long history of use in Eastern Europe and Asia for traumatic brain injury, stroke, and neurodegenerative conditions. Its relevance to PTSD lies in its neurotrophic and neuroprotective properties.

Mechanisms: Cerebrolysin mimics the activity of endogenous neurotrophic factors including BDNF, NGF, NT-3, and CNTF. It promotes neurogenesis in the hippocampus and has been shown to reduce apoptosis in neurons under stress conditions. It also has anti-inflammatory effects in the CNS.

TBI-PTSD overlap: A substantial proportion of PTSD cases — particularly in military populations — occur alongside traumatic brain injury. Cerebrolysin's evidence base in TBI recovery makes it relevant here. For that specific application, see our peptides for TBI guide.

Research limitations: Cerebrolysin lacks large RCTs specifically for PTSD. Most evidence is in TBI and dementia contexts, with PTSD application being extrapolated from mechanistic overlap.

Neuroplasticity as the Central Target

A unifying framework for understanding all of these peptides is their shared capacity to promote neuroplasticity. Fear extinction — the core process that successful PTSD treatment must facilitate — is a form of new learning that requires synaptic plasticity in the prefrontal cortex and hippocampus.

Converging evidence suggests that peptides enhancing BDNF (Semax, Selank, cerebrolysin) or supporting dopaminergic and serotonergic tone (BPC-157, Selank) may create a neurobiological environment more permissive to extinction learning. This has led some researchers to propose peptides as potential adjuncts to trauma-focused psychotherapy.

Stacking Considerations

Some researchers combine multiple peptides targeting different PTSD mechanisms. A common starting approach might include:

  • Selank (intranasal) for anxiolytic and BDNF effects
  • BPC-157 (oral or subcutaneous) for systemic protection and gut-brain axis support
  • DSIP for sleep normalization — disrupted sleep is universal in PTSD

Our best peptide stacks guide provides frameworks for combining peptides safely.

Safety and Regulatory Context

No peptide is FDA-approved for PTSD treatment. All use in this context is experimental and should occur under informed medical supervision. The most rigorous evidence for PTSD treatment remains trauma-focused cognitive-behavioral therapy (TF-CBT) and EMDR, alongside SSRI pharmacotherapy.

Frequently Asked Questions

Q: Are peptides a replacement for trauma therapy? No. Peptides may theoretically support the neurobiological conditions that make trauma therapy more effective, but they are not a substitute for evidence-based psychotherapy. EMDR and prolonged exposure remain first-line treatments.

Q: Can Selank help with hyperarousal symptoms of PTSD? Preclinical and clinical anxiety research suggests Selank reduces physiological arousal and reactivity without sedation. Hyperarousal is a core PTSD symptom cluster, so there is theoretical relevance — but specific PTSD trials have not been conducted.

Q: How does BPC-157 relate to trauma? BPC-157's primary documented effects on PTSD-relevant mechanisms are through dopaminergic modulation, gut-brain axis support, and anti-inflammatory action. It is not a direct anxiolytic but may address biological substrates of PTSD.

Q: Is cerebrolysin available in the United States? Cerebrolysin is not FDA-approved and is not commercially available in the US. It is used clinically in many European and Asian countries. Research-grade versions exist but regulatory status varies.

Q: What is the best peptide for PTSD nightmares? DSIP has sleep-regulatory properties and may reduce stress-axis activation during sleep. Some researchers also explore BPC-157 for sleep quality through HPA normalization. Neither is clinically validated specifically for PTSD nightmares.

Recommended Products

Quality supplements mentioned in this article

Minerals

Iron (Bisglycinate)

THORNE · Iron Bisglycinate

$20-25

Other

Alpha Lipoic Acid (ALA)

Nutricost · Alpha Lipoic Acid

$30-35

Affiliate disclosure: We may earn a commission from purchases made through these links at no extra cost to you. This helps support our research.

Disclaimer: This article is for informational and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement, peptide, or health protocol. Individual results may vary.

Want to optimize your health?

Create your free account and start optimizing your health today.

Sign Up Free